ARID1A and neoplasm: Mouse models of OCCC lacking ARID1A activity display increased survival and reduced ascites accumulation and tumor progression when treated with the pan‐HDAC inhibitor SAHA,83 making HDAC inhibition a very promising strategy for mutant ARID1A OCCC and OEC.